Fluocinolone acetonide intravitreal implant - Bausch and Lomb/pSivida

Drug Profile

Fluocinolone acetonide intravitreal implant - Bausch and Lomb/pSivida

Alternative Names: Fluocinolone acetonide Envision TD implant; Retisert

Latest Information Update: 22 May 2014

Price : $50

At a glance

  • Originator Bausch & Lomb; pSivida Inc
  • Developer Bausch & Lomb
  • Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Phospholipase A2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Uveitis
  • Discontinued Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema

Most Recent Events

  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 23 Jul 2007 Discontinued - Preregistration for Uveitis in European Union (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top